{"preliminary_commentary":{"by_channel":{"x_thread":18,"youtube":10,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03269136\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"MagnetisMM-1","nct_id":"NCT03269136","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=magnetismm-1-nct03269136. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"BCMA-CD3 bispecific antibody","label":"PF-06863135","type":"EXPERIMENTAL"},{"description":"BCMA-CD3 bispecific antibody + dexamethasone","label":"PF-06863135 + dexamethasone","type":"EXPERIMENTAL"},{"description":"BCMA-CD3 bispecific antibody + lenalidomide","label":"PF-06863135 + lenalidomide","type":"EXPERIMENTAL"},{"description":"BCMA-CD3 bispecific antibody + pomalidomide","label":"PF-06863135 + pomalidomide","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-01-19","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"enrollment":{"count":101,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"PF-06863135 monotherapy IV or SC","otherNames":["BCMA-CD3 bispecific antibody"],"type":"DRUG"},{"name":"PF-06863135 + dexamethasone","otherNames":["BCMA-CD3 bispecific antibody + dexamethasone"],"type":"DRUG"},{"name":"PF-06863135 + lenalidomide","otherNames":["BCMA-CD3 bispecific antibody + lenalidomide"],"type":"DRUG"},{"name":"PF-06863135 + pomalidomide","otherNames":["BCMA-CD3 bispecific antibody + pomalidomide"],"type":"DRUG"}],"last_update":"2025-03-18","lead_sponsor":"Pfizer","official_title":"MAGNETISMM-1 A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC AND CLINICAL ACTIVITY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) - CD3 BISPECIFIC ANTIBODY, AS A SINGLE AGENT AND IN COMBINATION WITH IMMUNOMODULATORY AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA (MM)","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2024-01-19","type":"ACTUAL"},"primary_outcomes":[{"measure":"Part 1: Number of Participants With Drug Limiting Toxicities (DLTs) Graded According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version (v)4.03","timeFrame":"Cycle 1 (21 Days)"},{"measure":"Part 2: Objective Response Rate (ORR) as Per International Myeloma Working Group (IMWG) Criteria","timeFrame":"From the first dose of study treatment until the first documented sCR or CR or PR or VGPR or new anti-cancer therapies or death, whichever occurred first (maximum up to 34.3 months)"},{"measure":"Part 2: Duration of Response (DOR) as Per IMWG Criteria","timeFrame":"From the first documentation of objective tumor response to first documentation of objective tumor progression or new anti-cancer therapies or death, whichever occurred first, (maximum up to 34.3 months)"}],"references":[{"citation":"Hibma JE, Irby D, Liu A, Elmeliegy M, King LE, Gifondorwa D, Jiang S, Poels KE, Soltantabar P, Lon HK, Shtylla B, Wang D, Williams JH, Nicholas T. Elranatamab Population Pharmacokinetics and Exposure-Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma. Clin Pharmacokinet. 2026 Aug;65(8):1173-1192. doi: 10.1007/s40262-026-01663-z. Epub 2026 Jun 13.","pmid":"42287565","type":"DERIVED"},{"citation":"Lon HK, Hibma J, Jiang S, Sullivan S, Vandendries E, Skoura A, Wang D, Elmeliegy M. Population Exposure-Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma. Target Oncol. 2025 Sep;20(5):803-819. doi: 10.1007/s11523-025-01168-y. Epub 2025 Aug 18.","pmid":"40826257","type":"DERIVED"},{"citation":"Elmeliegy M, Viqueira A, Vandendries E, Hickman A, Conte U, Irby D, Hibma J, Lon HK, Piscitelli J, Soltantabar P, Skoura A, Jiang S, Wang D. Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma. Target Oncol. 2025 Mar;20(2):349-359. doi: 10.1007/s11523-025-01134-8. Epub 2025 Feb 25.","pmid":"40000533","type":"DERIVED"},{"citation":"Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, Tomasson MH, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Gasparetto C, Chu MP, Dalovisio A, Sebag M, Lesokhin AM. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023 Oct;29(10):2570-2576. doi: 10.1038/s41591-023-02589-w. Epub 2023 Oct 2.","pmid":"37783970","type":"DERIVED"}],"start_date":{"date":"2017-11-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT03269136"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/magnetismm-1-nct03269136"}